The Role of PCSK9 Inhibitors in Managing Patients With Familial Hypercholesterolemia
WebcastFaculty
OVERVIEW
The Role of PCSK9 Inhibitors in Managing Patients With Familial Hypercholesterolemia is organized by Academic CME and will be held during Mar 09, 2017 - Mar 08, 2018.
The target audience for this medical event is Cardiologists, internal medicine, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of familial hypercholesterolemia. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.
This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.
Conference Objectives are :
• Review PCSK9 science and updated standards of care for the diagnosis, FH scoring, and management patients and their families with familial hypercholesterolemia
• Analyze clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data.
• Implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Cardiologists, internal medicine, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of familial hypercholesterolemia. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.
This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.
Conference Objectives are :
• Review PCSK9 science and updated standards of care for the diagnosis, FH scoring, and management patients and their families with familial hypercholesterolemia
• Analyze clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data.
• Implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia.
Additional details will be posted as soon as they are available.
SPECIALITIES
CardiologyRELATED ONLINE COURSES
Quick Links